1Kasiske BL,Chakkera HA,Louis TA,et al.A meta-analysis of immunosuppression withdrawal trials in renal transplantation[].Journal of the American Society of Nephrology.2000
2Pascual M,Curtis J,Delmonico F,et al.A prospective, randomized clinical trial of cyclosporine reduction in stable patients greater than 12 months after renal transplantation[].Transplantation.2003
3Lo A,Alloway RR.Strategies to reduce toxicities and improve outcomes in renal transplant recipients[].Pharmacotherapy.2002
4Wali RK,Drachenberg C,Hirsch HH,et al.BK virus-associated nephropathy in renal allograft recipients: rescue therapy by sirolimus-based immunosuppression[].Transplantation.2004
5Hocker B,John U,Plank C,et al.Successful withdrawal of steroids in pediatric renal transplant recipients receiving cyclosporine A and mycophenolate mofetil treatment: results after four years[].Transplantation.2004
6Abou-Jaoude MM,Ghantous I,Najm R,et al.Daclizumab versus anti-thymocyte globulin-fresenius as induction therapy for low-risk kidney transplant recipients[].Transplantation.2003
7Kreis H, Oberbauer R,Campistol J, et al.Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal[].Journal of the American Society of Nephrology.2004
8Charpentier B,Rostaing L,Berthoux F.A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients[].Transplantation.2003
9Chow F,Polkinghome K,Saunder A,et al.Historical controlled trial of OKT3 versus basiliximab induction therapy in simultaneous pancreas-renal transplantation[].Nephrology.2003
10Flavio V.Immunosuppression Minimization: Current and future trends in transplant immunosuppression[].American Journal of Transplantation.2003
